In vitro, Tan et al. (2020) further demonstrated that the activation of RIP3/MLKL-dependent necroptosis could increase the therapeutic sensitivity to gefitinib in NSCLC patients. The gene discussed is RIPK3; the disease is non-small cell lung carcinoma.